Sara Garrido, MD
Hematology & Oncology · Miami, FLNPI 1245227594
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AstraZeneca at 25.9% of the total. 2025 is the largest year on record at $240, more than ten times the $12 reported in 2021. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 18 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$122
- Novartis$90
- Tempus AI, Inc$66
- Puma Biotechnology, Inc.$61
- Daiichi Sankyo Inc.$48
- Gilead$46
- plus $39 from 1 others
What the payments were for
- Food & beverage$45997%
- Education$123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $122 |
| Novartis | 3 | $90 |
| Tempus AI, Inc | 3 | $66 |
| Puma Biotechnology, Inc. | 3 | $61 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Gilead | 2 | $46 |
| Merck | 2 | $39 |
How this compares
$471 in reported general payments places this provider in the 20th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TukysaTucatinib | 14 | $293,199 |
| EliquisApixaban | 36 | $20,327 |
| Exemestane | 79 | $15,180 |
| Anastrozole | 280 | $4,831 |
| Risedronate Sodium | 37 | $3,433 |
| Letrozole | 78 | $2,146 |
| Alendronate Sodium | 45 | $345 |
| Famotidine | 12 | $142 |
| Ondansetron OdtOndansetron | 11 | $60 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.